[Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes].

Autor:	González-Fernández MÁ; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España. Electronic address: mariaangeles.gonzalez.fernandez@salud.madrid.org., Herranz-Pinto P; Servicio de Dermatología. Hospital Universitario La Paz, Madrid, España., Alonso-Pacheco ML; Servicio de Dermatología. Hospital Universitario La Paz, Madrid, España., Mateo-Salillas C; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España., Hoyo-Muñoz Á; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España., Jiménez-Nácher I; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España., Moreno-Ramos F; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España., Herrero-Ambrosio A; Servicio de Farmacia. Hospital Universitario La Paz, Madrid, España.
Jazyk:	Spanish; Castilian
Zdroj:	Journal of healthcare quality research [J Healthc Qual Res] 2024 Jan-Feb; Vol. 39 (1), pp. 13-22. Date of Electronic Publication: 2023 Oct 31.
DOI:	10.1016/j.jhqr.2023.10.004
Abstrakt:	Introduction: Patient-reported outcomes (PROs) provide subjective information about their disease, treatment, and quality of life. Objective: To introduce a new system of work coordinated between pharmacists and dermatologists, based on the collection and analysis of PROs to assess its clinical impact as well as patients satisfaction. Method: A prospective single-centre observational study was conducted under clinical conditions and included adult patients diagnosed with psoriasis (PS) and atopic dermatitis (AD) between April-2021 and February-2022. Pharmacists and dermatologists agreed on this systematic work. A REDCap® database was designed to facilitate data collection and the subsequent analysis. Results: A total of 288 and 41 patients with PS and AD, respectively, were included. Those who started treatment showed significant improvement with a decrease in PROs and clinical parameters (p < 0.001). The pharmacist made 168 and 7 recommendations to dermatologists for PS and AD patients, respectively, of which 66.07% and 57.1% were accepted. The most common recommendations were «consult with rheumatologist» (20.83%), «extend drug regimen» (19.64%) and «consider change in treatment» (11.90%). Adverse events were reported in 55 and 17 patients with PS and AD, respectively. Of 103 patients, 75% were «very satisfied» and 20% «satisfied» with the system. Conclusions: This new working system helps to evaluate the short and long-term effectiveness of treatments and also to identify adverse events, alarm symptoms and co-morbidities in order to optimize therapies. Collaboration between pharmacists and dermatologists reduces decision-making time and patients appreciate better clinical care leading to higher patient satisfaction. (Copyright © 2023 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu